Capricor Therapeutics
Yahoo Finance • last year
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-Completed Targeted Enrollment for HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy- -On Track to Report Interim Futility Analysis in Fourth Quarter of 2023; Successful Outcome Would Trigger Milestone Payment to Capric... Full story
Yahoo Finance • last year
Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and... Full story
Yahoo Finance • last year
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program
SAN DIEGO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and... Full story
Yahoo Finance • last year
Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society
-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002’s Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy- -Company’s StealthX™ Technology Shows Promise of Exosome-Based Delivery of ASOs- SAN DIEGO,... Full story
Yahoo Finance • last year
Capricor Therapeutics Announces $23 Million Registered Direct Offering
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and... Full story
Yahoo Finance • last year
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy
-FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002’s Path Towards a Biologics License Application (BLA)- -Company On Track to Complete HOPE-3 Enrollment and Report Outcome from Interim Analysis in Q4... Full story
Yahoo Finance • last year
Capricor Therapeutics Appoints Michael Kelliher to Board of Directors
SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of musc... Full story
Yahoo Finance • last year
Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors
-John Hopkins School of Medicine Clinical Director Joins Capricor’s Board of Directors with over 30 Years of Internal Medicine and Infectious Disease Experience- SAN DIEGO, July 13, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ... Full story
Yahoo Finance • last year
Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
-Improvements in Left Ventricular Ejection Fraction (LVEF) for the Majority of Patients Suggest Preservation of Cardiac Function- -Results in Performance of the Upper Limb PUL v2.0 Continue to Show Long-Term Benefit in Skeletal Muscle Fun... Full story
Yahoo Finance • last year
Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and... Full story
Yahoo Finance • 2 years ago
Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform
SAN DIEGO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of musc... Full story
Yahoo Finance • 2 years ago
Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy (DMD); Plan to Report on Interim Analysis in Q4 2023- -Held Type-B CMC Meeting withU.S. Food and Drug Administration (FDA)... Full story
Yahoo Finance • 2 years ago
Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and... Full story
Yahoo Finance • 2 years ago
Capricor Therapeutics Receives Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award
SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and... Full story
Yahoo Finance • 2 years ago
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan
-Expands Partnership with Nippon Shinyaku to Japan to Leverage Deep Experience in Drug Development for Rare Diseases and Commercial DMD Franchise- -Capricor to Receive an Upfront Payment of $12 Million, Additional Potential Milestone Pa... Full story
Yahoo Finance • 2 years ago
Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18 Months, Demonstrating Long-Term Benefit in Skeletal Muscle Function- -Results Continue to Suggest Potential Disease Modification in Duchen... Full story
Yahoo Finance • 2 years ago
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program
-Company to present 18-month data results from ongoing HOPE-2 open label extension trial of CAP-1002 in patients with Duchenne muscular dystrophy- -Webinar to be held on Wednesday, January 25, 2023 at 1:00 p.m. ET- SAN DIEGO, Jan. 19, 2... Full story
Yahoo Finance • 2 years ago
Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform
-StealthX™Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins- SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the... Full story
Yahoo Finance • 2 years ago
Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-Enrollment Continues to Progress in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy- -Presented Positive One-Year Safety and Efficacy Results From HOPE-2 Open Label Extension Study of CAP-1002 in Duc... Full story
Yahoo Finance • 2 years ago
Capricor Therapeutics to Present Third Quarter 2022 Financial Results and Recent Corporate Update on November 10
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and... Full story
